Lineage Cell Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $35,442 | $11,355 |
| Marketable securities | 50 | 46,520 |
| Accounts receivable, net (Note 3) | 745 | 297 |
| Prepaid expenses and other current assets | 2,204 | 1,828 |
| Total current assets | 38,441 | 60,000 |
| NONCURRENT ASSETS | ||
| Property and equipment, net (Notes 6 and 14) | 4,767 | 5,673 |
| Deposits and other long-term assets | 577 | 627 |
| Goodwill | 10,672 | 10,672 |
| Intangible assets, net | 46,562 | 46,692 |
| TOTAL ASSETS | $101,019 | $123,664 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | $6,270 | $8,608 |
| Operating lease liabilities, current portion (Note 14) | 830 | 916 |
| Finance lease liabilities, current portion (Note 14) | 52 | 36 |
| Deferred revenues, current portion (Note 3) | 10,808 | 9,421 |
| Total current liabilities | 17,960 | 18,981 |
| LONG-TERM LIABILITIES | ||
| Deferred tax liability (Note 13) | 273 | 2,076 |
| Deferred revenues, net of current portion (Note 3) | 18,693 | 27,725 |
| Operating lease liabilities, net of current portion (Note 14) | 1,979 | 2,860 |
| Finance lease liabilities, net of current portion (Note 14) | 91 | 84 |
| Other long-term liabilities | — | 2 |
| TOTAL LIABILITIES | 38,996 | 51,728 |
| Commitments and contingencies (Note 14) | ||
| SHAREHOLDERS’ EQUITY | ||
| Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of December 31, 2023 and 2022 | — | — |
| Common shares, no par value, 450,000 and 250,000 shares authorized as of December 31, 2023 and 2022, respectively; 174,987 and 170,093 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 451,343 | 440,280 |
| Accumulated other comprehensive loss | (3,068) | (3,571) |
| Accumulated deficit | (384,856) | (363,370) |
| Lineage's shareholders’ equity | 63,419 | 73,339 |
| Noncontrolling deficit | (1,396) | (1,403) |
| Total shareholders’ equity | 62,023 | 71,936 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $101,019 | $123,664 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.